» Articles » PMID: 34522163

Otorhinolaryngological Management in Taiwanese Patients with Mucopolysaccharidoses

Overview
Journal Int J Med Sci
Specialty General Medicine
Date 2021 Sep 15
PMID 34522163
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Mucopolysaccharidoses (MPSs) are lysosomal storage disorders wherein glycosaminoglycans accumulate because the enzymes that degrade them are insufficient. The earliest symptoms, which are the main reasons for seeking consultation, are otorhinolaryngological and commonly occur in MPS I, II, IV, and VI. This retrospective study aimed to determine the occurrence of otorhinolaryngological manifestations in MPS patients in Taiwan and to analyze the prognosis of surgical intervention, including its effect on symptoms. We reviewed 42 patients (30 males and 12 females), with a median age of 20.5 years, who had MPS (16.7% type I, 35.7% type II, 19.0% type IIIB, 21.4% type IVA, and 7.2% type VI). The following otorhinolaryngological manifestations were collected: annual number of upper respiratory tract infections (URTIs) and otitis media with effusion (OME) episodes, adenoid size, tonsillar size, and apnea-hypopnea index (AHI). Among 42 patients, we found recurrent otitis media in 42.9% of the patients, hearing loss in 83.3% (mixed: 52.4%, conductive: 21.4%, and sensorineural: 9.5%), frequent URTIs in 47.6%, and obstructive sleep apnea syndrome in 35.7%. Moreover, 76% of the patients underwent ear, nose, and throat (ENT) surgery, including adenoidectomy, tonsillectomy, tympanostomy with ventilation tube insertion, tracheotomy, and supraglottoplasty. MPS patients had a high incidence of ENT problems. ENT surgery reduced the severity of hearing loss, degree of symptoms related to upper airway obstruction, and severity of respiratory tract and otological infections of patients with MPS.

Citing Articles

Hearing loss in patients with Morquio A syndrome: A scoping review.

Diaz-Ordonez L, Duque-Cordoba P, Silva-Cuero K, Gutierrez-Medina J, Saldarriaga W, Murgasova L Medicine (Baltimore). 2025; 104(2):e41128.

PMID: 39792720 PMC: 11730861. DOI: 10.1097/MD.0000000000041128.


Otorhinolaryngological Problems in Mucopolysaccharidoses: A Review of Common Symptoms in a Rare Disease.

Wasniewska-Wlodarczyk A, Pepas R, Rosiak O, Konopka W Brain Sci. 2024; 14(11).

PMID: 39595849 PMC: 11591799. DOI: 10.3390/brainsci14111085.


[Characterization of otorhinolaryngologic manifestations in children with mucopolysaccharide storage disease typeⅠand type Ⅱ].

Bai X, Liu R, Feng S, Pu J, Gu Q Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2024; 38(3):221-224.

PMID: 38433691 PMC: 11233216. DOI: 10.13201/j.issn.2096-7993.2024.03.008.


Immunomodulatory role of metalloproteinase ADAM17 in tumor development.

Wang K, Xuan Z, Liu X, Zheng M, Yang C, Wang H Front Immunol. 2022; 13:1059376.

PMID: 36466812 PMC: 9715963. DOI: 10.3389/fimmu.2022.1059376.


The Anesthetic Strategy for Patients with Mucopolysaccharidoses: A Retrospective Cohort Study.

Lao H, Lin Y, Liang M, Yang Y, Huang Y, Chan Y J Pers Med. 2022; 12(8).

PMID: 36013292 PMC: 9410098. DOI: 10.3390/jpm12081343.


References
1.
Chan Y, Lin S, Man T, Cheng C . Clinical experience in anesthetic management for children with mucopolysaccharidoses: Report of ten cases. Acta Paediatr Taiwan. 2001; 42(5):306-8. View

2.
Motamed M, Thorne S, Narula A . Treatment of otitis media with effusion in children with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol. 2000; 53(2):121-4. DOI: 10.1016/s0165-5876(00)00320-7. View

3.
Muenzer J . The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr. 2004; 144(5 Suppl):S27-34. DOI: 10.1016/j.jpeds.2004.01.052. View

4.
Peck J . Hearing loss in Hunter's syndrome--mucopolysaccharidosis II. Ear Hear. 1984; 5(4):243-6. DOI: 10.1097/00003446-198407000-00009. View

5.
Pelley C, Kwo J, Hess D . Tracheomalacia in an adult with respiratory failure and Morquio syndrome. Respir Care. 2007; 52(3):278-82. View